Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

411 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Control and Elimination of Hepatitis C Virus Among People With HIV in Australia: Extended Follow-up of the CEASE Cohort (2014-2023).
Martinello M, Carson JM, Post JJ, Finlayson R, Baker D, Read P, Shaw D, Bloch M, Doyle J, Hellard M, Filep E, Hosseini-Hooshyar S, Dore GJ, Matthews GV. Martinello M, et al. Among authors: read p. Open Forum Infect Dis. 2024 Dec 17;11(12):ofae665. doi: 10.1093/ofid/ofae665. eCollection 2024 Dec. Open Forum Infect Dis. 2024. PMID: 39691290 Free PMC article.
Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
Hosseini-Hooshyar S, Martinello M, Yee J, Read P, Baker D, Post JJ, Finlayson R, Bloch M, Doyle JS, Shaw D, Hellard M, Petoumenos K, Carson J, Dore GJ, Matthews GV; CEASE study team. Hosseini-Hooshyar S, et al. Among authors: read p. AIDS. 2020 Jul 15;34(9):1347-1358. doi: 10.1097/QAD.0000000000002562. AIDS. 2020. PMID: 32590433
Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct-acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort.
Bartlett SR, Verich A, Carson J, Hosseini-Hooshyar S, Read P, Baker D, Post JJ, Finlayson R, Bloch M, Doyle JS, Shaw D, Hellard M, Martinez M, Marks P, Dore GJ, Matthews GV, Applegate T, Martinello M. Bartlett SR, et al. Among authors: read p. Health Sci Rep. 2022 Aug 18;5(5):e719. doi: 10.1002/hsr2.719. eCollection 2022 Sep. Health Sci Rep. 2022. PMID: 36000082 Free PMC article.
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ; SIMPLIFY Study Group. Grebely J, et al. Among authors: read p. Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161. doi: 10.1016/S2468-1253(17)30404-1. Epub 2018 Jan 6. Lancet Gastroenterol Hepatol. 2018. PMID: 29310928 Free article. Clinical Trial.
Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study.
Bajis S, Grebely J, Cooper L, Smith J, Owen G, Chudleigh A, Hajarizadeh B, Martinello M, Adey S, Read P, Gilliver R, Applegate T, Treloar C, Maher L, Dore GJ. Bajis S, et al. Among authors: read p. J Viral Hepat. 2019 Aug;26(8):969-979. doi: 10.1111/jvh.13112. Epub 2019 May 2. J Viral Hepat. 2019. PMID: 30980785
Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs.
Cunningham EB, Hajarizadeh B, Amin J, Hellard M, Bruneau J, Feld JJ, Cooper C, Powis J, Litwin AH, Marks P, Dalgard O, Conway B, Moriggia A, Stedman C, Read P, Bruggmann P, Lacombe K, Dunlop A, Applegate TL, Matthews GV, Fraser C, Dore GJ, Grebely J. Cunningham EB, et al. Among authors: read p. Clin Infect Dis. 2021 Apr 26;72(8):1392-1400. doi: 10.1093/cid/ciaa253. Clin Infect Dis. 2021. PMID: 32166305
Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial.
Grebely J, Read P, Cunningham EB, Weltman M, Matthews GV, Dunlop A, Montebello M, Martinello M, Gilliver R, Marks P, Applegate TL, Dore GJ; DARLO‐C Study Group. Grebely J, et al. Among authors: read p. Health Sci Rep. 2020 Mar 15;3(2):e151. doi: 10.1002/hsr2.151. eCollection 2020 Jun. Health Sci Rep. 2020. PMID: 32270056 Free PMC article.
Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort.
Carson JM, Hajarizadeh B, Hanson J, O'Beirne J, Iser D, Read P, Balcomb A, Davies J, Doyle JS, Yee J, Martinello M, Marks P, Dore GJ, Matthews GV; REACH-C Study Group. Carson JM, et al. Among authors: read p. Int J Drug Policy. 2021 Oct;96:103422. doi: 10.1016/j.drugpo.2021.103422. Epub 2021 Aug 21. Int J Drug Policy. 2021. PMID: 34426040
High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study.
Yee J, Carson JM, Hajarizadeh B, Hanson J, O'Beirne J, Iser D, Read P, Balcomb A, Doyle JS, Davies J, Martinello M, Marks P, Dore GJ, Matthews GV; REACH‐C Study Group. Yee J, et al. Among authors: read p. Hepatol Commun. 2022 Mar;6(3):496-512. doi: 10.1002/hep4.1826. Epub 2021 Nov 2. Hepatol Commun. 2022. PMID: 34729957 Free PMC article.
411 results